Payment overview · 2025
General Payments
$85.24
2 reported records · 2 companies
Healthcare provider profile · identity verified
Deepa Subramanian, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · HOLIDAY, FL · NPI 1588744429
Verified facts
What the public records show
CMS Open Payments records show Deepa Subramanian, M.D received $85.24 in general payments during 2025 across 2 reported records.
LEO Pharma Inc. accounted for 73.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $62.95 | 73.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.29 | 26.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.24 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPEVIGO Normalized: spevigo |
Biological | LEO Pharma Inc. | $62.95 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 622 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 140 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 443 | 125 |
| Omeprazole | Omeprazole | 400 | 108 |
| Lisinopril | Lisinopril | 395 | 107 |
| Fluticasone Propionate | Fluticasone Propionate | 352 | 133 |
| Alprazolam | Alprazolam | 330 | 58 |
| Losartan Potassium | Losartan Potassium | 308 | 82 |
| Gabapentin | Gabapentin | 304 | 95 |
| Famotidine | Famotidine | 276 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 68 |
| Tramadol Hcl | Tramadol Hcl | 216 | 47 |
| Trazodone Hcl | Trazodone Hcl | 210 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 40 |
| Simvastatin | Simvastatin | 205 | 58 |
| Furosemide | Furosemide | 200 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 48 |
| Metformin Hcl | Metformin Hcl | 191 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 49 |
| Lorazepam | Lorazepam | 163 | 30 |
| Montelukast Sodium | Montelukast Sodium | 163 | 41 |
| Baclofen | Baclofen | 157 | 55 |
| Potassium Chloride | Potassium Chloride | 156 | 48 |
| Prednisone | Prednisone | 154 | 90 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 41 |
| Eliquis | Apixaban | 129 | 36 |
| Temazepam | Temazepam | 128 | 15 |
| Carvedilol | Carvedilol | 126 | 35 |
| Atenolol | Atenolol | 122 | 30 |
| Clonazepam | Clonazepam | 122 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 121 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 106 | 92 |
| Pregabalin | Pregabalin | 102 | 23 |
| Spironolactone | Spironolactone | 99 | 26 |
| Sertraline Hcl | Sertraline Hcl | 98 | 27 |
| Meloxicam | Meloxicam | 95 | 29 |
| Warfarin Sodium | Warfarin Sodium | 93 | 22 |
| Glipizide Er | Glipizide | 90 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 18 |
| Glimepiride | Glimepiride | 82 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 80 | 20 |
| Allopurinol | Allopurinol | 79 | 22 |
| Celecoxib | Celecoxib | 78 | 22 |
| Metformin Hcl Er | Metformin Hcl | 78 | 26 |
| Ezetimibe | Ezetimibe | 73 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 72 | 11 |
| Mirtazapine | Mirtazapine | 70 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 68 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 67 | 54 |
| Meclizine Hcl | Meclizine Hcl | 67 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 31 |
| Azithromycin | Azithromycin | 64 | 54 |
| Xarelto | Rivaroxaban | 64 | 15 |
| Myrbetriq | Mirabegron | 62 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 21 |
| Jardiance | Empagliflozin | 61 | 16 |
| Methylprednisolone | Methylprednisolone | 61 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 34 |
| Memantine Hcl | Memantine Hcl | 60 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | 22 |
| Benazepril Hcl | Benazepril Hcl | 58 | 11 |
| Folic Acid | Folic Acid | 58 | 13 |
| Sucralfate | Sucralfate | 58 | 29 |
| Ibuprofen | Ibuprofen | 57 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 50 | 16 |
| Ozempic | Semaglutide | 49 | 16 |
| Topiramate | Topiramate | 48 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 21 |
| Glipizide | Glipizide | 47 | 14 |
| Lovastatin | Lovastatin | 47 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 44 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Latanoprost | Latanoprost | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Nystatin | Nystatin | 30 | 20 |
| Valsartan | Valsartan | 30 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 16 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 17 | 16 |
| Anastrozole | Anastrozole | 16 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Diazepam | Diazepam | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.24 · 2 records | LEO Pharma Inc. | SPEVIGO, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error